Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy 1st Edition

Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy, 1st Edition by Vivek Asati and Ankur Vaidya offers a timely, authoritative exploration of how heterocyclic chemistry is reshaping modern oncology. Perfect for medicinal chemists, cancer researchers, and advanced students, this volume zeroes in on the molecular targets that make heterocyclic scaffolds so powerful in drug discovery.

Delving into key target classes—kinases, topoisomerases, apoptosis regulators, epigenetic enzymes and more—the book translates complex mechanisms into practical design strategies. Readers will find clear discussions of structure–activity relationships, lead optimization approaches, and emerging trends that bridge bench research and therapeutic potential. Case studies and up-to-date literature syntheses provide real-world context for translational research.

What sets this edition apart is its balance of depth and clarity: rigorous enough for specialist use, yet accessible for interdisciplinary teams in academia and industry. Whether you’re developing hit-to-lead compounds, evaluating target selectivity, or surveying the landscape of next-generation anticancer agents, this resource equips you with actionable insights and a strategic framework for heterocyclic drug design.

A must-have for libraries and personal collections, Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy is essential for professionals across the global oncology community—from India and Europe to North America and the Asia-Pacific—seeking to accelerate discovery and translate chemistry into effective cancer therapies. Add this compelling reference to your shelf and stay at the forefront of heterocyclic approaches in cancer drug development.

Note: eBooks do not include supplementary materials such as CDs, access codes, etc.